Forge Medical

Forge Biologics, now part of Ajinomoto Group/Ajinomoto Bio‑Pharma Services, operates as a leading US-based gene therapy CDMO specializing in high-yield adeno-associated virus (AAV) vector manufacturing. It offers end-to-end solutions from early development through clinical trials to commercial production. Its proprietary FUEL™ platform enables significant productivity gains over industry standards. The company has supported more than 50 clients across over 35 indications and manufactured over 500 batches to date. While it also develops its own gene therapies, most public information centers on its role as an advanced contract manufacturer and technology partner rather than on specific internal drug candidates.